Pegylated liposomal doxorubicin (PLD) clinical trials
4 indexed studies · 3 currently recruiting
- RecruitingPHASE3
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
This study is testing a new medicine, Sofetabart Mipitecan, for certain ovarian, fallopian tube, and peritoneal cancers. It aims to see if it works better than current treatments and is safe, for people whose cancer either has or hasn't responded well to previous platinum-based treatments.
For: Ovarian Neoplasms · Fallopian Tube Neoplasms · Peritoneal NeoplasmsUnited States · Australia · Austria - RecruitingPHASE3
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
This study is looking into a new drug, AZD5335, for women with advanced ovarian cancer that has become resistant to usual chemotherapy. It compares AZD5335 to existing treatments to see if it works better at controlling the cancer's growth.
For: Epithelial Ovarian CancerUnited States · Australia · Belgium - RecruitingPHASE3
A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01)
This study is looking at a new medicine called Mocertatug Rezetecan (Mo-Rez) for women with ovarian cancer that hasn't responded well to previous platinum-based treatments. It aims to see if Mo-Rez works better or is safer than current standard treatments. It's a key step in understanding this new option.
For: Ovarian NeoplasmsAustralia · Canada · Japan - Active not recruitingPHASE3
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer
This study is testing a new drug called Rina-S for platinum-resistant ovarian cancer. It compares Rina-S to standard chemotherapy treatments. You have an equal chance of receiving Rina-S or a standard chemotherapy. All participants receive active treatment, no placebo.
For: Platinum-resistant Ovarian CancerUnited States · Australia · Austria